ACSL1 and metabolic dysfunction-associated steatotic liver disease: In addition, qRT-PCR and western blot results showed that NAFLD model cells treated with Antagomir-103-3p displayed inhibition of fatty acid synthase (FASN) and long-chain acyl coenzyme A synthase 1 (ACSL1) mRNA levels and FASN and ACSL1 protein expression while promoting ACOX1 mRNA and protein expression (Fig. 2D).